NiKang Therapeutics
Wilmington, CN · Founded 2017 · 7 known investors
NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2. It focuses on precision medicine for difficult-to-drug oncology targets, with three compounds advanced into first-in-human clinical testing.
Founders & leadership
NiKang Therapeutics was founded in 2017 by Yan Lou.
YL
Yan LouFounder
GY
Gary YeungNamed on SEC filing
TJ
Ting JiaNamed on SEC filing
H(
Hong (Kelsey) ChenChief Financial Officer
ZG
Zhenhai GaoPresident, CEO, and Secretary
RW
Roderick WongNamed on SEC filing
WF
Wei FuNamed on SEC filing
ZY
Zhengbin YaoNamed on SEC filing
SC
Sean CaoNamed on SEC filing
Investors · 7
Reported raises · per SEC filings
Form D private placements▶$200MraisedJun 2021 · 30 investors · BiotechnologyRule 506(b)
▶$200MraisedJun 2021 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary YeungDirector
- Ting JiaDirector
- Hong (Kelsey) ChenExecutive Officer
- Zhenhai GaoExecutive Officer, Director
- Roderick WongDirector
- Wei FuDirector
- Zhengbin YaoDirector
- Sean CaoDirector
- Offering amount
- $200M
- Amount sold
- $200M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapBioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Tango Therapeutics3 shared keywordsTango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors. The company focuses on expanding access to precision cancer therapies for patients.
Nkarta, Inc.3 shared keywordsNkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments. Its lead program, NKX019, targets the CD19 antigen for B cell-mediated autoimmune conditions such as lupus nephritis and systemic sclerosis.
Companies competing with NiKang Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does NiKang Therapeutics do?
- NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2. It focuses on precision medicine for difficult-to-drug oncology targets, with three compounds advanced into first-in-human clinical testing.
- Who founded NiKang Therapeutics?
- NiKang Therapeutics was founded by Yan Lou in 2017.
- Who are NiKang Therapeutics's investors?
- NiKang Therapeutics's investors include EcoR1 Capital, LAV, Lilly Asia Ventures, RA Capital, Samsara BioCapital, The Innovation Space, Logos.
- Where is NiKang Therapeutics headquartered?
- NiKang Therapeutics is headquartered in Wilmington, CN.